Thu, February 22, 2018
Wed, February 21, 2018
Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018
Wed, February 14, 2018
Tue, February 13, 2018
Mon, February 12, 2018
Fri, February 9, 2018
Thu, February 8, 2018
Wed, February 7, 2018

Alethia Young Maintained (VRTX) at Buy with Increased Target to $196 on, Feb 13th, 2018


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-196-on-feb-13th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Alethia Young of Credit Suisse, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $195 to $196 on, Feb 13th, 2018.

Alethia has made no other calls on VRTX in the last 4 months.



There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $200 on, Friday, February 2nd, 2018
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $197 on, Thursday, February 1st, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $191 on, Thursday, February 1st, 2018
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $200 on, Thursday, February 1st, 2018

Publication Contributing Sources